| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01470989 | β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) | PHASE3 | COMPLETED | 136 | — | — | Nov 1, 2011 | May 1, 2013 | Jul 9, 2021 | 56 | United States, Australia +7 |
Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline,or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.
| Arm | Type | Description |
|---|---|---|
| canakinumab | EXPERIMENTAL | canakinumab 150 mg s.c. |
| Name | Type | Description |
|---|---|---|
| ACZ885 | DRUG | canakinumab 150 mg s.c., given on demand upon new flares |
| Triamcinolone acetonide 40 mg | DRUG | Participants received 40 mg intramuscular (IM) |
Inclusion Criteria: * Patients who have completed the second extension studies CACZ885H2356E2 or CACZ885H2357E2 * Patients treated with canakinumab in the core studies or subsequent extensions Exclusion Criteria: \- Pregnant or nursing (lactating) women